April 17, 12-1pm, Seminar Room 1, TRF
Presented by Professor
Chris Sobey
NHMRC Senior Research Fellow and Professor in Physiology
Co-Head, Vascular Biology & Immunopharmacology Group,
La Trobe University
Stroke
accounts for more than 10% of deaths worldwide, and over a third of survivors
are left with major neurological impairment. The need for new and effective
therapies for stroke is therefore clear and urgent. While some advances have
been made toward understanding its mechanisms, still only one intervention has
been found to reduce brain injury following clinical stroke – the ‘clot-buster’
recombinant tissue plasminogen activator. Unfortunately however, with a short
time window of only 4.5 h, this therapy is available to less than 10% of stroke
patients. For further advances in the clinical treatment of ischemic stroke,
the complex mechanisms of cellular injury following cerebral ischemia must be
elucidated to provide novel targets for future therapies. This presentation
will describe some of our recent work examining novel therapies such as human
amnion epithelial cells and vitamin D in experimental stroke models.
Chris Sobey is an
NHMRC Senior Research Fellow and Professor in Physiology who moved from the
Monash Pharmacology Department to the School of Life Sciences at La Trobe
University in 2017. There, together with Prof Grant Drummond, the new HOD of
Physiology Anatomy & Microbiology, Chris co-leads the Vascular Biology
& Immunopharmacology Group comprising 20 members. Chris has more than 190
publications and an H index of 56 from his studies of vascular diseases
involving oxidative stress and inflammation – especially stroke, atherosclerosis
and hypertension. His current work is investigating the inflammatory mechanisms
occurring in the brain after stroke in order to identify and develop new
treatments for stroke patients. Novel approaches include systemic cell therapy,
Th2 cytokines, estrogen receptor binding drugs and vitamin D.
No comments:
Post a Comment